Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850465 | 0.89 | PPARD (0.54) | PPARDFFAR1TP53LMNAMAPT | |
| SCHEMBL1733090 | 0.84 | TTR (0.48) | TP53TTRLMNAPTGDR2SMN1; SMN2 | |
| SCHEMBL4854113 | 0.82 | PPARD (0.53) | PPARDFFAR1TP53TTRMAPT | |
| SCHEMBL5387584 | 0.76 | TTR (0.65) | TTRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL4851206 | 0.75 | PPARD (0.44) | PPARDFFAR1TP53MAPT | |
| SCHEMBL2097759 | 0.74 | FFAR1 (0.53) | PPARDFFAR1TP53LMNAMAPT | |
| SCHEMBL1731684 | 0.74 | KDR (0.53) | PPARDFFAR1TP53TTRLMNA | |
| SCHEMBL2413521 | 0.74 | SMN1; SMN2 (0.51) | PPARDFFAR1TP53LMNAMAPT | |
| SCHEMBL6243768 | 0.73 | PPARD (0.73) | PPARDFFAR1MAPT | |
| SCHEMBL4847898 | 0.73 | NPC1 (0.48) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1852433-B1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZERIA PHARM CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-1852433-B1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZERIA PHARM CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1852433-A1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Zeria Pharmaceutical Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1852433-A1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Zeria Pharmaceutical Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| CN-101048402-A | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARM CO LTD (JP) | 2007-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | CEL, LIPC, CES1 | PPARD 130/4885FFAR1 77/4885TP53 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.